Insider Selling: Anteris Technologies Global (NASDAQ:AVR) Major Shareholder Sells $1,415,240.10 in Stock

Posted by John Perry on Aug 13th, 2026

Anteris Technologies Global Corp. (NASDAQ:AVR – Get Free Report) major shareholder L1 Capital Pty Ltd sold 174,721 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $8.10, for a total value of $1,415,240.10. Following the transaction, the insider directly owned 5,439,000 shares of the company’s stock, valued at approximately $44,055,900. The trade was a 3.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

L1 Capital Pty Ltd also recently made the following trade(s):

On Tuesday, August 11th, L1 Capital Pty Ltd sold 375,815 shares of Anteris Technologies Global stock. The stock was sold at an average price of $9.30, for a total value of $3,495,079.50.
On Monday, August 10th, L1 Capital Pty Ltd sold 251,844 shares of Anteris Technologies Global stock. The shares were sold at an average price of $9.10, for a total value of $2,291,780.40.
On Tuesday, August 4th, L1 Capital Pty Ltd sold 480,608 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.30, for a total value of $3,989,046.40.
On Wednesday, August 5th, L1 Capital Pty Ltd sold 14,581 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.23, for a total value of $120,001.63.
On Monday, August 3rd, L1 Capital Pty Ltd sold 475,693 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.10, for a total value of $3,853,113.30.
On Friday, July 31st, L1 Capital Pty Ltd sold 48,711 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.15, for a total transaction of $396,994.65.
On Wednesday, July 29th, L1 Capital Pty Ltd sold 155,505 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.04, for a total transaction of $1,250,260.20.
On Thursday, July 30th, L1 Capital Pty Ltd sold 558,633 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.20, for a total transaction of $4,580,790.60.
On Monday, July 27th, L1 Capital Pty Ltd sold 232,817 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.19, for a total transaction of $1,906,771.23.
On Tuesday, July 28th, L1 Capital Pty Ltd sold 208,731 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.09, for a total transaction of $1,688,633.79.

Anteris Technologies Global Price Performance

NASDAQ AVR opened at $8.87 on Thursday. Anteris Technologies Global Corp. has a 12 month low of $3.30 and a 12 month high of $11.06. The company has a market capitalization of $863.42 million, a P/E ratio of -4.55 and a beta of 1.78. The company’s 50 day simple moving average is $9.15 and its 200 day simple moving average is $7.35.

Anteris Technologies Global (NASDAQ:AVR – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09). The business had revenue of $1.01 million for the quarter, compared to the consensus estimate of $1.50 million. Anteris Technologies Global had a negative return on equity of 110.36% and a negative net margin of 4,619.27%.During the same quarter in the previous year, the business posted ($0.58) earnings per share. On average, analysts anticipate that Anteris Technologies Global Corp. will post -1.14 earnings per share for the current year.

Key Stories Impacting Anteris Technologies Global

Here are the key news stories impacting Anteris Technologies Global this week:

Positive Sentiment: Q2 loss narrowed and sales increased: Anteris reported a second-quarter 2026 loss of $0.30 per share, an improvement from the $0.58 loss recorded a year earlier. Net sales rose to $1.01 million, although the figure remained below the $1.50 million analyst estimate. Anteris Technologies Q2 Loss Narrows, Net Sales Rise
Positive Sentiment: Medicare reimbursement eligibility supports the clinical program: The company said eligible U.S. sites in its global pivotal PARADIGM trial can receive Medicare reimbursement under a Centers for Medicare & Medicaid Services national coverage policy. This could improve trial execution and reduce financial barriers to participation. Anteris Technologies Announces Results for the Second Quarter of 2026
Neutral Sentiment: Development-stage profile remains central to the outlook: Anteris continues investing heavily in medical-device development, reflected in its extremely negative net margin and negative return on equity. Investors are likely focused on clinical milestones, commercialization prospects and future funding needs rather than near-term profitability.
Negative Sentiment: Quarterly results missed expectations: The $0.30-per-share loss was wider than the consensus estimate of $0.21, while revenue also fell short of expectations. The earnings miss can weigh on the stock despite year-over-year improvement. Anteris Technologies Global earnings report
Negative Sentiment: Major shareholder continues reducing its position: L1 Capital Pty Ltd disclosed sales of 375,815 shares on August 11 and 251,844 shares on August 10, following earlier sales including 174,721 shares on August 6. The repeated selling, totaling more than 800,000 shares across these disclosures, creates additional supply and may signal reduced conviction or portfolio rebalancing. SEC filing on L1 Capital share sales

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on AVR. Barclays increased their price target on Anteris Technologies Global from $17.00 to $18.00 and gave the company an “overweight” rating in a research report on Friday, May 15th. Wall Street Zen raised shares of Anteris Technologies Global from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Anteris Technologies Global in a research report on Friday, May 29th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Read Our Latest Stock Analysis on AVR

Institutional Trading of Anteris Technologies Global

Several hedge funds and other institutional investors have recently modified their holdings of AVR. Militia Capital Management LLC purchased a new stake in Anteris Technologies Global in the 1st quarter worth about $3,358,000. Avidity Partners Management LP purchased a new position in Anteris Technologies Global during the 1st quarter valued at about $832,000. Assenagon Asset Management S.A. acquired a new position in shares of Anteris Technologies Global in the 2nd quarter valued at about $6,350,000. SummitTX Capital L.P. purchased a new stake in shares of Anteris Technologies Global in the first quarter worth approximately $1,326,000. Finally, Perceptive Advisors LLC lifted its position in shares of Anteris Technologies Global by 104.4% in the first quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company’s stock worth $19,011,000 after purchasing an additional 1,750,000 shares in the last quarter.

Anteris Technologies Global Company Profile

(Get Free Report)

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.